Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

European Journal of Haematology

Volumn 83, Issue 2, 2009, Pages 154-155

  Huang, Jocelin ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; DRUG ACTIVITY; ERYTHROPOIESIS; HUMAN; LETTER; LEUKEMIA; MYELOID METAPLASIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; MALE; PRIMARY MYELOFIBROSIS;

EID: 67650766311     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01266.x     Document Type: Letter

References (10)

1. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007 78 : 183 205. (Pubitemid 46246531)
2. Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992 79 : 29 37.
3. Barosi G, Liberato LN, Guarnone R. Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1993 83 : 365 9.
4. Hasselbalch HC, Clausen NT, Jensen BA. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. Am J Hematol 2002 70 : 92 9.
5. Tefferi A, Silverstein MN. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1994 86 : 893. (Pubitemid 24194459)
6. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004 127 : 399 403. (Pubitemid 39536591)
7. Tefferi A, Strand JJ, Lasho TL, et al. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Cancer 2006 106 : 1739 43.
8. Tsiara SN, Chaidos A, Bourantas LK, Kapsali HD, Bourantas KL. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol 2007 117 : 156 61.
9. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008 112 : 2726 32.
10. Tefferi A. Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor? Mayo Clin Proc 2007 82 : 1316 8.